menafrivac
Vaccineexperimental
Clinical trial activity
3 trials · 10 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
1
Earliest trial started May 1, 2010 (NCT01119482)
Timeline
Indications
Approved for
Mechanism of action
- Neisseria meningitidisImmunity, active
Neisseria meningitidis immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- menafrivac
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06879327 | Phase 2 | May 30, 2025 | PATH, Pharmassist Ltd |
| NCT03746665 | Phase 3 | Dec 19, 2018 | Department of State for Health and Social Welfare, The Gambia, Public Health England, Stanford University, University of Cambridge, University of London, World Health Organization |
| NCT01119482 | Phase 4 | May 1, 2010 | Bill and Melinda Gates Foundation, University of London, Wellcome Trust |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of London | Academic/Hospital | 2 | 2 | 2 | 2010 |
| Bill and Melinda Gates Foundation | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Department of State for Health and Social Welfare, The Gambia | Academic/Hospital | 1 | 0 | 1 | 2018 |
| PATH | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Pharmassist Ltd | For profit | 1 | 0 | 1 | 2025 |
| Public Health England | Government | 1 | 0 | 1 | 2018 |
| Stanford University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of Cambridge | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Wellcome Trust | Academic/Hospital | 1 | 0 | 1 | 2010 |
| World Health Organization | Government | 1 | 0 | 1 | 2018 |
10 organizations
Page 1 / 1